Anke Hilse Maitland-van der Zee

Summary

Affiliation: Utrecht University
Country: The Netherlands

Publications

  1. pmc Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study
    Anke Hilse Maitland-van der Zee
    School of Public Health, University of Texas Health Science Center at Houston, 1200 Hermann Pressler, Houston TX, USA
    Am Heart J 153:54-8. 2007
  2. ncbi request reprint Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences UIPS, Utrecht University, Sorbonnelaan 16, P O BOX 80082, The Netherlands
    Atherosclerosis 163:213-22. 2002
  3. ncbi request reprint Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS)
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Acta Cardiol 61:327-31. 2006
  4. ncbi request reprint Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects
    Anke Hilse Maitland-van der Zee
    Human Genetics Center, University of Texas Health Science Centre, Houston, TX 77030, USA
    Am J Hypertens 18:1077-83. 2005
  5. ncbi request reprint A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide
    Anke Hilse Maitland-van der Zee
    Human Genetics Center, University of Texas Health Science Center, Houston, TX 77030, USA
    Pharmacogenet Genomics 15:287-93. 2005
  6. ncbi request reprint Pharmacogenetics of response to statins: where do we stand?
    Anke Hilse Maitland-van der Zee
    Human Genetics Center, Health Science Center at Houston, University of Texas, 1200 Hermann Pressler, Houston, TX 77030, USA
    Curr Atheroscler Rep 7:204-8. 2005
  7. ncbi request reprint Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism
    Anke Hilse Maitland-van der Zee
    Atherosclerosis 175:377-9. 2004
  8. ncbi request reprint Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Pharmacogenetics 13:219-23. 2003
  9. ncbi request reprint The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Pharmacogenetics 12:647-53. 2002
  10. ncbi request reprint Epistatic effect of cholesteryl ester transfer protein and hepatic lipase on serum high-density lipoprotein cholesterol levels
    Aaron Isaacs
    Genetic Epidemiology Unit, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands
    J Clin Endocrinol Metab 92:2680-7. 2007

Collaborators

Detail Information

Publications13

  1. pmc Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study
    Anke Hilse Maitland-van der Zee
    School of Public Health, University of Texas Health Science Center at Houston, 1200 Hermann Pressler, Houston TX, USA
    Am Heart J 153:54-8. 2007
    ....
  2. ncbi request reprint Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences UIPS, Utrecht University, Sorbonnelaan 16, P O BOX 80082, The Netherlands
    Atherosclerosis 163:213-22. 2002
    ..Determining the genotype will not deny therapy to a subject, but will help in deciding the therapy that will suit the patient best...
  3. ncbi request reprint Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS)
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Acta Cardiol 61:327-31. 2006
    ..corrected] The influence ofApoE polymorphism on the efficacy of statins in lowering plasma lipids and lipoproteins and improving angiographic parameters was assessed...
  4. ncbi request reprint Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects
    Anke Hilse Maitland-van der Zee
    Human Genetics Center, University of Texas Health Science Centre, Houston, TX 77030, USA
    Am J Hypertens 18:1077-83. 2005
    ..The aim of this study was to characterize interindividual variation in glucose and lipid responses to hydrochlorothiazide and to identify demographic, environmental, and genetic predictors associated with this variation...
  5. ncbi request reprint A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide
    Anke Hilse Maitland-van der Zee
    Human Genetics Center, University of Texas Health Science Center, Houston, TX 77030, USA
    Pharmacogenet Genomics 15:287-93. 2005
    ..To assess the influence of variations in multiple candidate genes on inter-individual variation in diastolic blood pressure (DBP) response to hydrochlorothiazide...
  6. ncbi request reprint Pharmacogenetics of response to statins: where do we stand?
    Anke Hilse Maitland-van der Zee
    Human Genetics Center, Health Science Center at Houston, University of Texas, 1200 Hermann Pressler, Houston, TX 77030, USA
    Curr Atheroscler Rep 7:204-8. 2005
    ..Even though many studies have been performed, few results have been replicated. It is our contention that larger sample sizes and consideration of multiple genes are needed in the field of pharmacogenetics of statin response...
  7. ncbi request reprint Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism
    Anke Hilse Maitland-van der Zee
    Atherosclerosis 175:377-9. 2004
  8. ncbi request reprint Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Pharmacogenetics 13:219-23. 2003
    ..18 (CI 1.01-10.03) in men. The apoE genotype is associated with discontinuation of statins. This suggests that subjects who are genetically prone to develop hypercholesterolemia show the highest risk of discontinuation of treatment...
  9. ncbi request reprint The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Pharmacogenetics 12:647-53. 2002
    ..The protective effect of statins on total mortality was not statistically significant, but did not seem to differ between subjects with different apoE genotypes...
  10. ncbi request reprint Epistatic effect of cholesteryl ester transfer protein and hepatic lipase on serum high-density lipoprotein cholesterol levels
    Aaron Isaacs
    Genetic Epidemiology Unit, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands
    J Clin Endocrinol Metab 92:2680-7. 2007
    ..The objectives of the current study were to characterize the effect of the hepatic lipase variant, and its interaction with the CETP variant, in terms of cholesterol levels, atherosclerosis, and risk of myocardial infarction (MI)...
  11. doi request reprint Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant
    Bas J M Peters
    Division of Pharmacoepidemiology and Pharmacotherapy, Faculty of Science, Utrecht University, Utrecht, The Netherlands
    Pharmacogenet Genomics 18:631-6. 2008
    ..Therefore, we assessed whether the effectiveness of statins in reducing the risk of MI was modified by the GNB3 C825T polymorphism...
  12. pmc Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertensi
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Pharmacogenet Genomics 18:651-6. 2008
    ..High homocysteine blood concentrations predispose to coronary artery disease and statins influence homocysteine levels...
  13. ncbi request reprint Pharmacogenomics of coumarin anticoagulants: are we underestimating the role of CYP2C9?
    Tom Schalekamp
    Thromb Haemost 100:175-6. 2008